Colcrys and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Colcrys (colchicine), especially for people who are male, 60+ old, also take Eliquis, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Colcrys. It is created by eHealthMe based on reports of 4,414 people who have side effects when taking Colcrys from the FDA, and is updated regularly.

What is Colcrys?

Colcrys has active ingredients of colchicine. It is often used in gout. eHealthMe is studying from 4,546 Colcrys users. Check the latest studies of Colcrys.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,321 drugs and 3,597 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

4,414 people reported to have side effects when taking Colcrys.
Among them, 13 people (0.29%) have Agranulocytosis.

Among these 13 people:

What is the gender of people who have Agranulocytosis when taking Colcrys? *

female: 25 %
male: 75 %

What is the age of people who have Agranulocytosis when taking Colcrys? *

What are other drugs people take besides Colcrys? *

What are other side effects people have besides Agranulocytosis? *

Diarrhea: 2 people, 15.38%
Full Blood Count Decreased: 2 people, 15.38%
Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 15.38%
Fever: 2 people, 15.38%
Feeling Hot: 2 people, 15.38%
Febrile Neutropenia (fever with reduced white blood cells): 2 people, 15.38%
Dyspnea (difficult or laboured breathing): 2 people, 15.38%
Drug Toxicity: 2 people, 15.38%
Nausea And Vomiting: 2 people, 15.38%
White Blood Cell Count Decreased: 1 person, 7.69%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 15.38%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 15.38%
Psoriasis (immune-mediated disease that affects the skin): 2 people, 15.38%
Pain: 2 people, 15.38%
High Blood Pressure: 2 people, 15.38%
Rhinitis (a medical term for irritation and inflammation of the mucous membrane inside the nose): 2 people, 15.38%
Nausea (feeling of having an urge to vomit): 2 people, 15.38%
Muscle Spasms (muscle contraction): 2 people, 15.38%
Multiple Myeloma (cancer of the plasma cells): 2 people, 15.38%
Depression: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Colcrys and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Colcrys:

Colcrys (4,546 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

Browse all side effects of Colcrys:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,321 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,597 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on colchicine (the active ingredients of Colcrys) and Colcrys (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.